Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
Open Access
- 6 March 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 11 (3), 1-5
- https://doi.org/10.1038/s41408-021-00446-y
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | National Institutes of Health (R01-GM066099, R01-AG061105, R01-GM066099, R01-AG061105)
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | National Institutes of Health
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
- UT | University of Texas MD Anderson Cancer Center (MDS/AML Moon Shot)
This publication has 15 references indexed in Scilit:
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesNature Medicine, 2020
- Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesBlood Advances, 2020
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignanciesScience, 2019
- APR-246 reactivates mutant p53 by targeting cysteines 124 and 277Cell Death & Disease, 2018
- Targeting mutant p53 for efficient cancer therapyNature Reviews Cancer, 2017
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than othersNature Reviews Clinical Oncology, 2017
- Mutant p53 in Cancer: Accumulation, Gain-of-Function, and TherapyJournal of Molecular Biology, 2017
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesLeukemia, 2015
- Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck CancerCancer Research, 2015
- A formal perturbation equation between genotype and phenotype determines the Evolutionary Action of protein-coding variations on fitnessGenome Research, 2014